Business description: Exact Sciences Corporation

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Number of employees: 6,950

Sales by Activity: Exact Sciences Corporation

Fiscal Period: December20202021202220232024

Biotechnology (Startups)

1.49B 1.77B 2.08B 2.5B 2.76B
See all business segments

Geographical breakdown of sales: Exact Sciences Corporation

Fiscal Period: December20202021202220232024

United States

1.41B 1.66B 1.97B 2.35B 2.57B

Outside of United States

77.48M 110M 118M 153M 189M
See all geographic segments

Executive Committee: Exact Sciences Corporation

Manager TitleAgeSince
Chief Executive Officer 59 2009-03-17
Director of Finance/CFO 39 2024-04-14
Chief Tech/Sci/R&D Officer - 2021-12-31
Chief Tech/Sci/R&D Officer - 2018-12-31
Chief Tech/Sci/R&D Officer 53 2021-03-31
See EXACT SCIENCES CORPORATION governance

Composition of the Board of Directors: Exact Sciences Corporation

Director TitleAgeSince
Chairman 59 2014-03-20
Director/Board Member 70 2009-04-28
Director/Board Member 75 2010-07-18
Director/Board Member 79 2014-07-23
Director/Board Member 60 2022-12-29
Director/Board Member 52 2020-07-21
Director/Board Member 63 2021-03-17
Director/Board Member 64 2024-06-12
Director/Board Member 66 2025-01-01
Director/Board Member 54 2025-04-28
Composition of the Board of Directors

Shareholders: Exact Sciences Corporation

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.92 %
27,722,623 14.92 % 1 560 M $
Capital Research & Management Co. (World Investors)
9.601 %
17,835,277 9.601 % 1 004 M $
Vanguard Fiduciary Trust Co.
9.495 %
17,637,674 9.495 % 993 M $
Wellington Trust Co., NA
6.73 %
12,501,316 6.73 % 704 M $
BlackRock Advisors LLC
5.066 %
9,410,336 5.066 % 530 M $
List of EXACT SCIENCES CORPORATION shareholders

Holdings: Exact Sciences Corporation

NameEquities%Valuation
2,441,171 4.93% 5,138,665 $

Company details: Exact Sciences Corporation

EXACT Sciences Corp.

5505 Endeavor Lane

53719, Madison

+608 284 5700

http://www.exactsciences.com
address Exact Sciences Corporation(EXAS)

Group companies: Exact Sciences Corporation

NameCategory and Sector
Medical Specialties
See all subsidiaries

Bio Diagnostics & Testing

Change 5d. change 1-year change 3-years change Capi.($)
-0.91%-1.43%+17.15%+24.38% 9.91B
+0.21%-4.59%+29.03%-29.20% 2.55B
+1.21%+0.26%+18.50%+22.41% 2.09B
+1.73%+2.62%+225.93%+21.38% 1.6B
-1.63%+1.68%+59.62%-1.92% 1.11B
-0.47%-0.63%+34.78%-21.14% 1.06B
-6.57%-11.06%-76.90%-82.09% 618M
-0.73%-16.42%+32.17% - 399M
+2.43%-2.31%-70.86%-92.45% 304M
-1.27%-2.88% - - 178M
Average +0.40%-3.57%+29.93%-19.83% 1.98B
Weighted average by Cap. -0.18%-1.86%+35.22%+7.53%
See all sector performances
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
52.54USD
Average target price
68.86USD
Spread / Average Target
+31.06%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. EXAS Stock
  4. Company Exact Sciences Corporation